Skip to main content
Nicola Longo, MD, Medical Genetics, Los Angeles, CA

NicolaLongoMDPhD

Medical Genetics Los Angeles, CA

Clinical Biochemical Genetics, Clinical Genetics

Professor of Pediatrics, Chief, Division of Medical Genetics

Dr. Longo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Longo's full profile

Already have an account?

  • Office

    10833 Le Conte Ave
    Center for Health Sciences CHS 12-138
    Los Angeles, CA 90095
    Phone+1 310-923-0473
    Fax+1 310-206-8417

Education & Training

  • Univ Parma- Fac Med
    Univ Parma- Fac MedClass of 1982

Certifications & Licensure

  • AK State Medical License
    AK State Medical License 2020 - 2026
  • CA State Medical License
    CA State Medical License 2024 - 2026
  • UT State Medical License
    UT State Medical License 2001 - 2026
  • NV State Medical License
    NV State Medical License 2008 - 2025
  • WY State Medical License
    WY State Medical License 2011 - 2025
  • GA State Medical License
    GA State Medical License 1995 - 2001
  • American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
  • American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Utah DOH Identifies First Baby with Inherited Disorder That Primarily Affects Brain, Muscles
    Utah DOH Identifies First Baby with Inherited Disorder That Primarily Affects Brain, MusclesDecember 30th, 2020
  • Consensus Guideline for the Diagnosis and Treatment of Tetrahydrobiopterin (BH4) Deficiencies
    Consensus Guideline for the Diagnosis and Treatment of Tetrahydrobiopterin (BH4) DeficienciesMay 26th, 2020
  • Horizon Pharma Plc Announces FDA Approval to Expand the Age Range for RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid to Include Newborns
    Horizon Pharma Plc Announces FDA Approval to Expand the Age Range for RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid to Include NewbornsDecember 27th, 2018
  • Join now to see all

Other Languages

  • Italian